More on KYKOY

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:KYKOY)
Delayed: 14.33 +0.38 (2.72%)
Prev. Close $13.95  
Open$14.33 
52 Wk High$ 
52 Wk Low$ 
Day High$15.07 
Day Low$14.33 
P/E N/A  
EPS$ 
Volume1,068 

Friends, Peers and Foes (?): KNBWY, ARDX, BBIO, KY4 ORTX (more...)

Sep 29, 2026 08:00 AM Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
Jul 21, 2026 03:00 AM European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union
Jun 11, 2026 08:03 AM Kura Oncology reports positive long-term cancer drug trial data
Jun 11, 2026 08:02 AM Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
May 14, 2026 08:30 AM FDA approves dosing update for CRYSVITA in adults with rare bone disease
May 14, 2026 08:30 AM FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
May 12, 2026 09:40 AM Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
May 6, 2026 08:01 AM CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program
Apr 24, 2026 08:00 AM Kyowa Kirin begins phase 2 trial of ziftomenib in Japan for AML
Apr 24, 2026 08:00 AM Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
View All Articles

Entities mentioned with KYKOY

View All Entities